Patent · US Active

Ras inhibitory peptides and uses thereof

US10533039B2 · kind B2 · utility

4Cited by

76References

10Claims

0Family size

Assignee

President and Fellows of Harvard College · US

Inventors

Gregory L. Verdine · Boston, US
John Hanney McGee · Palo Alto, US

Key dates

Filing date	May 21, 2015
Grant date	Jan 14, 2020
Priority date	—
Expiry date	Oct 13, 2035

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides peptides comprising a sequence of X−6X−5X−4X−3X−2X−1X1PX3X4PX6X7PGX10X11AX13X14X15X16LX18X19X20X21X22X23LX25X26 YLX29X30X31X32 (SEQ ID NO: 13) wherein the amino acids X−6, X−5, X−4, X−3, X−2, X−1, X1, X3, X4, X6, X7, X10, X11, X13, X14, X15, X16, X18, X19, X20, X21, X22, X25, X26, X29, X30, X31, and X32 are as defined herein. The present invention further provides pharmaceutical compositions comprising the peptides and methods of using the peptides for treating proliferative diseases such as cancer which are associated with Ras. Also provided are methods of screening a library of peptide dimers using a peptide dimer display technology.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.